Post-ERCP Bowel Evisceration in a Liver Transplant Recipient Previously Treated with Atezolizumab�Bevacizumab: First Report
Hepatocellular carcinoma (HCC) treatment increasingly involves liver transplantation (LT), often after downstaging therapies. Atezolizumab, a PD-L1 inhibitor, combined with bevacizumab, an anti-VEGF agent, is widely used, showing high response rates pre-transplant. However, bevacizumab impairs angiogenesis and can significantly increase the risk of wound dehiscence, infection, and delayed healing after major surgery, including LT.
Authors
- Cécile Gomercic
- Maxime Thobois (ORCID: https://orcid.org/0009-0006-0411-2765)
- Michel Rayar (ORCID: https://orcid.org/0000-0003-3113-2260)
- Geoffroy Vanbiervliet (ORCID: https://orcid.org/0000-0003-2251-9076)
- Dann Ouizeman
- Elena Santos-Pérez (ORCID: https://orcid.org/0000-0002-6997-4028)
- Rodolphe Anty (ORCID: https://orcid.org/0000-0002-8053-1957)
- Anne-Claire Frin
Institutions
- Université Côte d'Azur (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Cognition Behaviour Technology (FR)
Publication Details
- Journal
- Revista Española de Enfermedades Digestivas
- Published
- 2025-01-01
- DOI
- https://doi.org/10.17235/reed.2025.11518/2025
- Citations
- 1
- Primary Topic
- Gastrointestinal disorders and treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01